Hypofractionated stereotactic reirradiation for recurrent glioblastoma

• Published in: Journal of neuro-oncology Vol. 120; no. 1; pp. 117 - 123
• Main Authors: Yazici, Gozde, Cengiz, Mustafa, Ozyigit, Gokhan, Eren, Gulnihan, Yildiz, Ferah, Akyol, Fadil, Gurkaynak, Murat, Zorlu, Faruk
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01-10-2014; Springer Nature B.V
• Subjects: Adult; Aged; Brain Neoplasms - mortality; Brain Neoplasms - pathology; Brain Neoplasms - surgery; Clinical Study; Dose Fractionation; Female; Follow-Up Studies; Glioblastoma - mortality; Glioblastoma - pathology; Glioblastoma - surgery; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Neoplasm Recurrence, Local - mortality; Neoplasm Recurrence, Local - pathology; Neoplasm Recurrence, Local - surgery; Neoplasm Staging; Neurology; Oncology; Prognosis; Radiosurgery - mortality; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult; Recurrent glioblastoma; Reirradiation; Cyberknife; Stereotactic radiotherapy
• ISSN: 0167-594X; 1573-7373
• DOI: 10.1007/s11060-014-1524-0

Treatment choices for recurrent glioblastoma patients are sparse and the results are not satisfactory. In this retrospective analysis, we evaluated the results of re-irradiation of locally recurrent glioblastoma patients with an image-guided, fractionated, frameless stereotactic radiotherapy (SRT) technique. We treated 37 patients with the diagnosis of recurrent glioblastoma from September 2009 to December 2011. SRT was performed in a median five fractions (range, 1–5 fractions) with CyberKnife
®
(Accuray Incorporated, Sunnyvale, CA, USA). The dose given ranged from 14 to 32 Gy (median, 30 Gy). The median volume of the GTV was 24 cc (range, 2–81 cc). Median follow-up was 9.3 months. Five patients had regression in their lesions, 14 had stable disease, progression was observed in eight patients, and seven patients had pseudoprogression. The median survival following SRT was 10.6 months (range, 1.1–20 months) and overall survival following initial treatment was 35.5 months. The time to progression following SRT was 7.9 months in median. Patients with pseudoprogression had significantly longer survival after the first magnetic resonance imaging (MRI) compared to those with regression, stable or progressive disease (
p
 = 0.012). The median survival after SRT for patients with pseudoprogression was 20 months. Patients who had GTV <24 cc had significantly longer survival following SRT compared to those with lesions ≥24 cc (
p
 = 0.015). Patients who had chemotherapy after SRT had a median survival of 16.8 months. This was 9.7 months for patients who were not prescribed any chemotherapy (
p
 = 0.062).